Should be taken on an empty stomach (i.e. At least one hour before food or two hours after food).
|
Metabolic or respiratory alkalosis, hypocalcaemia, hypochlorhydria, severe pulmonary oedema, unknown abdominal pain. IV: Conditions with Na intake restrictions (e.g. renal failure), hypoventilation, history of urinary calculi, coexisting K depletion, hypernatraemia. Patient with chloride loss due to vomiting or continuous gastrointestinal suction. IV: Concomitant use with diuretics known to produce hypochloraemic alkalosis.
|
Patient with CHF, hypertension, cirrhosis, on low Na diet; eclampsia, oedema, aldosteronism or other conditions associated with Na retention; oliguria or anuria. Avoid extravasation (IV). Renal and hepatic impairment. Children. Pregnancy and lactation. Monitoring Parameters Monitor serum electrolytes, including serum Ca; urinary pH, arterial blood gases if necessary. IV: Perform arterial blood gas analyses, especially arterial/venous blood pH and CO2 levels, prior to and during the treatment course. Monitor cardiac status, infusion site, and for signs of fluid retention.
|
Significant: Metabolic alkalosis, hypernatraemia; fluid and/or solute overload (IV); tissue necrosis, vascular irritation or sloughing (IV extravasation); decreased CSF pressure and intracranial haemorrhage (rapid IV inj in neonates).
Gastrointestinal disorders: Abdominal pain, flatulence, spontaneous stomach rupture, nausea, vomiting, unpleasant taste.
General disorders and administration site conditions: Unusual tiredness or weakness.
Metabolism and nutrition disorders: Fluid retention, hypocalcaemia, exacerbated hypokalaemia, loss of appetite.
Musculoskeletal and connective tissue disorders: Muscle spasms or cramps.
Nervous system disorders: Headache, restlessness.
Psychiatric disorders: Mood or mental changes, nervousness, extreme irritability.
Renal and urinary disorders: Frequent urge to urinate.
Respiratory, thoracic and mediastinal disorders: Pulmonary oedema, breathing difficulty, fluid in the lungs.
Vascular disorders: Hypertension.
|
|
|
Increased excretion of lithium, aspirin, methotrexate. Reduced excretion of quinidine, amphetamines, methadone, quinine, and ephedrine. Reduced absorption of tetracycline, rifampicin, ketoconazole, dipyridamole, chloroquine, phenothiazines, phenytoin, penicillamine. May increase the renal tubular reabsorption of mecamylamine. May reduce the serum K concentration with K supplements.
|
|
|
B05XA02 - sodium bicarbonate ; Belongs to the class of electrolyte solutions used in I.V. solutions.
B05CB04 - sodium bicarbonate ; Belongs to the class of salt solutions used as irrigating solutions.
|
Sign Out
